{"format":"alysly-page/1","url":"https://alysly.com/markets/stocks/roivant-sciences-ltd/","json":"https://alysly.com/json/markets/stocks/roivant-sciences-ltd/index.json","lang":"en-US","title":"Roivant Sciences Ltd. (ROIV) Stock Price Today | News","description":"Roivant Sciences Ltd. (ROIV). Revenue $8m, net margin -3629.2% (FY ended Mar 2026). ISIN BMG762791017. Held in 17 ETFs (top 0.29% in XUHL).","modified":"2026-11-02T00:00:00Z","alternates":[{"lang":"de-DE","url":"https://alysly.com/de/maerkte/aktien/roivant-sciences-ltd/","json":"https://alysly.com/json/de/maerkte/aktien/roivant-sciences-ltd/index.json"}],"about":"Machine-readable version of the page at url. It contains the text, tables and key figures published there, but not the interactive charts and tools.","breadcrumb":[{"name":"Markets","url":"https://alysly.com/markets/"},{"name":"Stocks","url":"https://alysly.com/markets/stocks/"},{"name":"Roivant Sciences Ltd.","url":"https://alysly.com/markets/stocks/roivant-sciences-ltd/"}],"content":[{"type":"heading","level":1,"text":"Roivant Sciences Ltd. (ROIV)"},{"type":"paragraph","text":"ROIV · Health Care · United States","links":[{"text":"Health Care","href":"https://alysly.com/markets/stocks/browse/?sector=Health%20Care"},{"text":"United States","href":"https://alysly.com/markets/stocks/browse/?country=United%20States"}]},{"type":"paragraph","text":"Roivant Sciences Ltd. (ROIV) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.29%. Anyone who holds an ETF containing Roivant Sciences also has an indirect stake in the company."},{"type":"heading","level":2,"id":"data","text":"Data and Charts: Roivant Sciences"},{"type":"heading","level":3,"text":"Key Data for Roivant Sciences"},{"type":"facts","items":[{"label":"Held in","value":"17 ETFs"},{"label":"Highest weight","value":"0.29%"},{"label":"Indices","value":"8"},{"label":"Sector","value":"Health Care"},{"label":"Country","value":"United States"},{"label":"ISIN","value":"BMG762791017"}]},{"type":"paragraph","text":"Data note 1","href":"#dn-1"},{"type":"heading","level":3,"text":"Roivant Sciences Stock Price Chart"},{"type":"paragraph","text":"The Roivant Sciences chart shows daily closing prices and is set to the current year by default. The stock is up 70.1% year to date and up 88.5% over twelve months. The last recorded close on October 30, 2026, was $36.91, at 78% of the 52-week range."},{"type":"paragraph","text":"Price series from our database since Sep 3, 2024, 543 daily values."},{"type":"paragraph","text":"Data note 2","href":"#dn-2"},{"type":"heading","level":3,"text":"Roivant Sciences Stock Performance"},{"type":"table","caption":"Roivant Sciences stock performance","rows":[["Year to date","+70.1%","1 year","+88.5%"],["1 month","+0.9%","3 months","+8.8%"],["Calendar year 2025","+83.4%","",""]]},{"type":"paragraph","text":"Data note 3","href":"#dn-3"},{"type":"paragraph","text":"Measured in euros, Roivant Sciences is up 78.9% year to date and up 94.9% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day."},{"type":"paragraph","text":"Data note 4","href":"#dn-4"},{"type":"heading","level":2,"id":"alysly","text":"Alysly Data Analysis: Roivant Sciences"},{"type":"heading","level":3,"text":"What ETF Is Roivant Sciences In?"},{"type":"paragraph","text":"Roivant Sciences has above-average ETF coverage and is held by 17 of the 104 ETFs we track, which together follow 8 indices. That puts the stock in more ETFs than 78.6% of the 4,341 stocks we track.","links":[{"text":"4,341 stocks we track","href":"https://alysly.com/markets/stocks/"}]},{"type":"paragraph","text":"Data note 5","href":"#dn-5"},{"type":"table","caption":"What ETF is Roivant Sciences in","columns":["ETF","Index","Weight","per €1,000 in the ETF"],"rows":[[{"text":"XUHL / XUHC","links":[{"text":"XUHL","href":"https://alysly.com/markets/etfs/xtrackers-msci-usa-health-care-ucits-etf-1c/"}]},{"text":"MSCI USA Health Care","href":"https://alysly.com/markets/indices/msci-usa-health-care/"},"0.29%","€2.90"],[{"text":"XDWH","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-health-care-ucits-etf-1c/"},{"text":"MSCI World Health Care","href":"https://alysly.com/markets/indices/msci-world-health-care/"},"0.22%","€2.15"],[{"text":"SPFS","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-world-health-care-ucits-etf/"},{"text":"MSCI World Health Care","href":"https://alysly.com/markets/indices/msci-world-health-care/"},"0.21%","€2.09"],[{"text":"XDEM","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-momentum-ucits-etf-1c/"},{"text":"MSCI World Momentum","href":"https://alysly.com/markets/indices/msci-world-momentum/"},"0.06%","€0.61"],[{"text":"XD9U / XD9D","links":[{"text":"XD9U","href":"https://alysly.com/markets/etfs/xtrackers-msci-usa-ucits-etf-1c/"}]},{"text":"MSCI USA","href":"https://alysly.com/markets/indices/msci-usa/"},"0.03%","€0.29"],[{"text":"XDWD / XDWL","links":[{"text":"XDWD","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-ucits-etf-1c/"}]},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.02%","€0.21"],[{"text":"SWWD","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-world-ucits-etf-dist/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.02%","€0.21"],[{"text":"SPPW","href":"https://alysly.com/markets/etfs/spdr-msci-world-ucits-etf/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.02%","€0.21"],[{"text":"EUNL","href":"https://alysly.com/markets/etfs/ishares-core-msci-world-ucits-etf-usd-acc/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.02%","€0.20"],[{"text":"WIMI","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-imi-ucits-etf-1c/"},{"text":"MSCI World IMI","href":"https://alysly.com/markets/indices/msci-world-imi/"},"0.02%","€0.20"],[{"text":"SPYY","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-all-country-world-ucits-etf-acc/"},{"text":"MSCI ACWI","href":"https://alysly.com/markets/indices/msci-acwi/"},"0.02%","€0.17"],[{"text":"IUSQ","href":"https://alysly.com/markets/etfs/ishares-msci-acwi-ucits-etf-usd-acc/"},{"text":"MSCI ACWI","href":"https://alysly.com/markets/indices/msci-acwi/"},"0.01%","€0.10"],[{"text":"SPYI / SPSA","links":[{"text":"SPYI","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-all-country-world-investable-market-ucits-etf-acc/"}]},{"text":"MSCI ACWI IMI","href":"https://alysly.com/markets/indices/msci-acwi-imi/"},"< 0.01%","< €0.05"]]},{"type":"paragraph","text":"Data note 6","href":"#dn-6"},{"type":"paragraph","text":"The last column shows how much of €1,000 in one of these funds goes to Roivant Sciences, based on each fund's latest holdings list."},{"type":"paragraph","text":"US-listed ETFs holding Roivant Sciences (weight per latest SEC filing): ONEQ 0.05%, VTI 0.02%. These funds are registered in the US; retail investors in the EU usually cannot buy them.","links":[{"text":"ONEQ","href":"https://alysly.com/markets/etfs/us/oneq/"},{"text":"VTI","href":"https://alysly.com/markets/etfs/us/vti/"}]},{"type":"list","ordered":false,"items":[{"text":"Roivant Sciences among the 4,341 stocks we track","href":"https://alysly.com/markets/stocks/etf-concentration/"},{"text":"Check the overlap of these 17 funds","href":"https://alysly.com/markets/etfs/overlap/"}]},{"type":"paragraph","text":"What's Inside Your ETF Portfolio and the ETF overlap check show how much Roivant Sciences overlaps with the rest of a portfolio.","links":[{"text":"What's Inside Your ETF Portfolio","href":"https://alysly.com/tools/portfolio-xray/"},{"text":"ETF overlap check","href":"https://alysly.com/tools/etf-overlap/"}]},{"type":"heading","level":3,"text":"What Roivant Sciences Executives and Directors Traded Recently"},{"type":"table","caption":"Trades by executives and directors","columns":["Date","Person","Type","Shares","Price"],"rows":[["Oct 28, 2026","Venker Eric Officer, President & Immunovant CEO","Sell (plan)","200,000","$36.59"],["Oct 20, 2026","Venker Eric Officer, President & Immunovant CEO","Sell (plan)","14,144","$35.42"],["Oct 20, 2026","Venker Eric Officer, President & Immunovant CEO","Sell (plan)","185,856","$35.09"],["Oct 1, 2026","Epperly Melissa B, Director","Sell (plan)","900","$36.57"],["Oct 1, 2026","Epperly Melissa B, Director","Sell (plan)","16,850","$36.08"],["Sep 30, 2026","Venker Eric Officer, President & Immunovant CEO","Sell (plan)","200,000","$36.62"]]},{"type":"paragraph","text":"The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded."},{"type":"paragraph","text":"“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32."},{"type":"paragraph","text":"Data note 7","href":"#dn-7"},{"type":"heading","level":3,"text":"Stocks With ETF Exposure Similar to Roivant Sciences"},{"type":"table","caption":"Stocks with ETF exposure similar to Roivant Sciences","columns":["Stock","Shared ETFs","r","1 year","Annualized volatility","Net margin","Revenue growth"],"rows":[["Roivant Sciences","–","–","+88.5%","39.4%","-3,629.2%","-71.6%"],[{"text":"Revolution Medicines","href":"https://alysly.com/markets/stocks/revolution-medicines-inc/"},"17","–","+225.0%","56.2%","–","–"],[{"text":"Insmed Incorporated","href":"https://alysly.com/markets/stocks/insmed-incorporated/"},"16","–","-42.0%","54.9%","-210.5%","+66.7%"],[{"text":"Medline","href":"https://alysly.com/markets/stocks/medline-inc-class-a/"},"16","–","–","43.8%","4.1%","+11.5%"],[{"text":"Natera","href":"https://alysly.com/markets/stocks/natera-inc/"},"16","–","+114.4%","46.7%","-9.0%","+35.9%"],[{"text":"Neurocrine Biosciences","href":"https://alysly.com/markets/stocks/neurocrine-biosciences-inc/"},"16","–","+5.8%","36.2%","16.7%","+21.4%"],[{"text":"United Therapeutics Corporation","href":"https://alysly.com/markets/stocks/united-therapeutics-corporation/"},"17","–","+32.0%","41.2%","41.9%","+10.6%"],[{"text":"Royalty Pharma Plc","href":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/"},"17","–","+81.9%","23.4%","32.4%","+5.1%"],[{"text":"Illumina","href":"https://alysly.com/markets/stocks/illumina-inc/"},"17","–","+138.3%","47.5%","19.6%","-0.7%"]]},{"type":"paragraph","text":"These stocks reach a portfolio through largely the same funds as Roivant Sciences. “Shared ETFs” counts the funds that hold both."},{"type":"paragraph","text":"Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical."},{"type":"paragraph","text":"Data note 8","href":"#dn-8"},{"type":"heading","level":2,"id":"fundamental","text":"Fundamental Analysis: Roivant Sciences"},{"type":"heading","level":3,"text":"Roivant Sciences Key Financials"},{"type":"facts","items":[{"label":"Revenue","value":"$8.3M"},{"label":"Net income","value":"-$299.8M"},{"label":"Diluted EPS","value":"-$0.54"},{"label":"Net margin","value":"-3,629.2%"},{"label":"Return on equity","value":"-6.6%"},{"label":"Equity ratio","value":"79.3%"},{"label":"Revenue growth","value":"-71.6%"}]},{"type":"paragraph","text":"Figures come from the SEC annual filing for the latest reported fiscal year (period end Mar 31, 2026)."},{"type":"table","caption":"Revenue and profit by fiscal year","columns":["Fiscal year","Revenue","Net income","Margin"],"rows":[["FY ended Mar 2024","0.0","4.3","13,294.2%"],["FY ended Mar 2025","0.0","-0.2","-592.0%"],["FY ended Mar 2026","0.0","-0.3","-3,629.2%"]]},{"type":"paragraph","text":"Data note 9","href":"#dn-9"},{"type":"heading","level":2,"id":"technical","text":"Technical Analysis: Roivant Sciences"},{"type":"heading","level":3,"text":"Roivant Sciences Risk Metrics"},{"type":"facts","items":[{"label":"Max drawdown","value":"-28.6%"},{"label":"Annualized volatility","value":"39.4%"}]},{"type":"paragraph","text":"Data note 10","href":"#dn-10"},{"type":"facts","items":[{"label":"Below peak","value":"-11.7%"},{"label":"Beta to S&P 500","value":"1.02"},{"label":"Correlation to S&P 500","value":"0.28"}]},{"type":"paragraph","text":"The close on Oct 30, 2026, was 11.7% below the highest close since Sep 3, 2024. That high was reached on Sep 9, 2026. When the S&P 500 rose or fell 1%, Roivant Sciences moved 1.02% on average in the same direction (past 252 trading days). The correlation of 0.28, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Roivant Sciences."},{"type":"paragraph","text":"Data note 11","href":"#dn-11"},{"type":"heading","level":3,"text":"What Roivant Sciences Correlates With"},{"type":"table","caption":"What Roivant Sciences Correlates With","columns":["Instrument","r","−1 … +1"],"rows":[[{"text":"SOLV","href":"https://alysly.com/markets/crypto/solv/"},"+0.55",""],[{"text":"Polkadot","href":"https://alysly.com/markets/crypto/polkadot/"},"+0.52",""],[{"text":"Cosmos","href":"https://alysly.com/markets/crypto/cosmos/"},"+0.45",""],[{"text":"SUSHI","href":"https://alysly.com/markets/crypto/sushi/"},"+0.44",""],[{"text":"RAY","href":"https://alysly.com/markets/crypto/ray/"},"+0.42",""],[{"text":"QKC","href":"https://alysly.com/markets/crypto/qkc/"},"+0.41",""],[{"text":"ACH","href":"https://alysly.com/markets/crypto/ach/"},"-0.60",""],[{"text":"SAPIEN","href":"https://alysly.com/markets/crypto/sapien/"},"-0.49",""],[{"text":"Stryker Corporation","href":"https://alysly.com/markets/stocks/stryker-corporation/"},"-0.34",""]]},{"type":"paragraph","text":"The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio."},{"type":"paragraph","text":"Data note 12","href":"#dn-12"},{"type":"heading","level":2,"id":"refs","text":"Related Content: Roivant Sciences"},{"type":"heading","level":3,"text":"Latest Investment Analysis: Stocks"},{"type":"list","ordered":false,"items":[{"text":"Oct 31, 2026 · Mixed Weekly Analysis: DAX Sets the Tone for the Week (+2.2%) · October 26–30, 2026","href":"https://alysly.com/analysis/weekly-analysis-dax-sets-tone-week-plus-2-2-percent-10312026/"},{"text":"Oct 24, 2026 · Risk-off Weekly Analysis: A Quiet Week, MSCI China -4.3% · October 19–23, 2026","href":"https://alysly.com/analysis/weekly-analysis-quiet-week-msci-china-minus-4-3-percent-10242026/"},{"text":"Oct 17, 2026 · Risk-off Weekly Analysis: S&P 500 Information Technology Weighs on the Week (-7.7%) · October 12–16, 2026","href":"https://alysly.com/analysis/weekly-analysis-sp-500-information-technology-weighs-week-10172026/"}]},{"type":"paragraph","text":"View all Investment Analysis","href":"https://alysly.com/analysis/"},{"type":"paragraph","text":"Updated Nov 2, 2026"},{"type":"heading","level":2,"id":"note-legend-h","text":"Data Notes"},{"type":"paragraph","text":"All calculations run automatically and are not investment advice."},{"type":"list","ordered":true,"items":[{"id":"dn-1","text":"Number of ETFs with available holdings data that hold the stock; the percentile compares all covered stocks against that same set."},{"id":"dn-2","text":"Price history from daily closing prices; one point per trading day."},{"id":"dn-3","text":"Returns computed automatically from the price series, excluding dividends, taxes and costs."},{"id":"dn-4","text":"Daily dollar prices converted at the same day's ECB euro reference rate, then measured like the dollar return."},{"id":"dn-5","text":"We count the funds we cover, not the market; the history covers the funds whose holdings reach back monthly."},{"id":"dn-6","text":"Holdings as of the fund's latest published holdings list; the as-of date is shown at the block."},{"id":"dn-7","text":"Purchases and sales by directors, officers and ten-percent owners from Form 4 filings with the US securities regulator, reported two trading days after the transaction."},{"id":"dn-8","text":"Selected by how many of the funds we track hold both names, not by business model."},{"id":"dn-9","text":"Latest reported fiscal year from XBRL annual filings with the SEC (public domain), figures in billions of US dollars; ratios computed from them."},{"id":"dn-10","text":"Computed from the full available price history."},{"id":"dn-11","text":"From daily closes: distance from the series' highest close; beta and correlation of daily returns to the S&P 500 over the last 252 trading days."},{"id":"dn-12","text":"Co-movement of daily returns over the last 90 trading days, across asset classes."}]},{"type":"paragraph","text":"Data and methodology: Alysly · Responsible for content: Alexander Bock","links":[{"text":"Alysly","href":"https://alysly.com/methodology/"},{"text":"Alexander Bock","href":"https://alysly.com/about/"}]},{"type":"paragraph","text":"View all data notes","href":"https://alysly.com/notes/"}],"structured_data":[{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://alysly.com/#org","name":"Alysly","url":"https://alysly.com/","logo":{"@type":"ImageObject","url":"https://alysly.com/img/icon-512.png","width":512,"height":512},"description":"Data-driven insights, transparent analysis and powerful tools for long-term investors.","email":"mail@alysly.com","contactPoint":{"@type":"ContactPoint","contactType":"customer support","email":"mail@alysly.com","availableLanguage":["de","en"]},"address":{"@type":"PostalAddress","addressLocality":"Haltern am See","postalCode":"45721","addressCountry":"DE"},"founder":{"@id":"https://alysly.com/#founder"},"sameAs":["https://www.linkedin.com/company/alyslycom/","https://www.youtube.com/@alyslycom","https://x.com/alyslycom"],"publishingPrinciples":"https://alysly.com/methodology/"},{"@type":"Person","@id":"https://alysly.com/#founder","name":"Alexander Bock","jobTitle":"Founder and data analyst","url":"https://alysly.com/about/","sameAs":["https://www.linkedin.com/in/abxk/"]},{"@type":"WebSite","@id":"https://alysly.com/#site","url":"https://alysly.com/","name":"Alysly","alternateName":"Alysly Investment Analysis","inLanguage":"en-US","publisher":{"@id":"https://alysly.com/#org"},"potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://alysly.com/markets/stocks/browse/?q={search_term_string}"},"query-input":"required name=search_term_string"}},{"@type":"WebPage","@id":"https://alysly.com/markets/stocks/roivant-sciences-ltd/#webpage","url":"https://alysly.com/markets/stocks/roivant-sciences-ltd/","name":"Roivant Sciences Ltd. – Alysly","description":"Roivant Sciences Ltd. (ROIV). Revenue $8m, net margin -3629.2% (FY ended Mar 2026). ISIN BMG762791017. Held in 17 ETFs (top 0.29% in XUHL).","inLanguage":"en-US","isPartOf":{"@id":"https://alysly.com/#site"},"dateModified":"2026-11-02T00:00:00Z","publisher":{"@id":"https://alysly.com/#org"},"mainEntity":{"@id":"https://alysly.com/markets/stocks/roivant-sciences-ltd/#entity"},"primaryImageOfPage":{"@type":"ImageObject","url":"https://alysly.com/og.png","width":1200,"height":630}}]},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Markets","item":"https://alysly.com/markets/"},{"@type":"ListItem","position":2,"name":"Stocks","item":"https://alysly.com/markets/stocks/"},{"@type":"ListItem","position":3,"name":"Roivant Sciences Ltd."}]},{"@context":"https://schema.org","@type":"Corporation","@id":"https://alysly.com/markets/stocks/roivant-sciences-ltd/#entity","name":"Roivant Sciences Ltd.","tickerSymbol":"ROIV","url":"https://alysly.com/markets/stocks/roivant-sciences-ltd/","mainEntityOfPage":"https://alysly.com/markets/stocks/roivant-sciences-ltd/","description":"Roivant Sciences Ltd. (ROIV). Revenue $8m, net margin -3629.2% (FY ended Mar 2026). ISIN BMG762791017. Held in 17 ETFs (top 0.29% in XUHL).","logo":"https://alysly.com/stock-logos/roivant-sciences-logo.webp","image":"https://alysly.com/stock-logos/roivant-sciences-logo.webp","identifier":[{"@type":"PropertyValue","propertyID":"TICKER","value":"ROIV"},{"@type":"PropertyValue","propertyID":"ISIN","value":"BMG762791017"}],"address":{"@type":"PostalAddress","addressCountry":"US"},"subjectOf":{"@type":"Dataset","name":"Roivant Sciences Ltd. — key figures","url":"https://alysly.com/markets/stocks/roivant-sciences-ltd/","description":"Roivant Sciences Ltd. (ROIV). Revenue $8m, net margin -3629.2% (FY ended Mar 2026). ISIN BMG762791017. Held in 17 ETFs (top 0.29% in XUHL).","inLanguage":"en-US","isAccessibleForFree":true,"creator":{"@id":"https://alysly.com/#org"},"publisher":{"@id":"https://alysly.com/#org"},"variableMeasured":[{"@type":"PropertyValue","name":"Held in ETFs","value":17},{"@type":"PropertyValue","name":"Highest ETF weight (%)","value":0.2904},{"@type":"PropertyValue","name":"YTD return (%)","value":70.1},{"@type":"PropertyValue","name":"1-year return (%)","value":88.5},{"@type":"PropertyValue","name":"Sector","value":"Health Care"},{"@type":"PropertyValue","name":"Revenue (USD)","unitText":"USD","value":8260000.0},{"@type":"PropertyValue","name":"Net income (USD)","unitText":"USD","value":-299771000.0},{"@type":"PropertyValue","name":"Total assets (USD)","unitText":"USD","value":5708687000.0},{"@type":"PropertyValue","name":"Shareholders equity (USD)","unitText":"USD","value":4527370000.0},{"@type":"PropertyValue","name":"Diluted EPS (USD)","value":-0.54},{"@type":"PropertyValue","name":"Net margin (%)","value":-3629.2000000000003},{"@type":"PropertyValue","name":"Return on equity (%)","value":-6.6000000000000005},{"@type":"PropertyValue","name":"Fiscal year end","value":"2026-03-31"}],"temporalCoverage":"2024-09-03/.."}}],"notice":"© 2026 Alysly.com. Not investment advice. All data without guarantee. Financial information is analyzed and presented partly with AI assistance."}